These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38036914)

  • 1. Association between hepatic steatosis and lipoprotein(a) levels in non-alcoholic patients: A systematic review.
    Masson W; Barbagelata L; Godinez-Leiva E; Genua I; Nogueira JP
    Indian J Gastroenterol; 2024 Jun; 43(3):536-547. PubMed ID: 38036914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
    Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Meroni M; Longo M; Lombardi R; Paolini E; Macchi C; Corsini A; Sirtori CR; Fracanzani AL; Ruscica M; Dongiovanni P
    Hepatol Commun; 2022 Mar; 6(3):535-549. PubMed ID: 34677008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults.
    Guo W; Lu J; Qin P; Li X; Zhu W; Wu J; Xu N; Zhang Q
    Lipids Health Dis; 2020 Oct; 19(1):218. PubMed ID: 33028338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease.
    Colak Y; Senates E; Ozturk O; Doganay HL; Coskunpinar E; Oltulu YM; Eren A; Sahin O; Ozkanli S; Enc FY; Ulasoglu C; Tuncer I
    Metab Syndr Relat Disord; 2012 Apr; 10(2):103-9. PubMed ID: 22112193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review.
    Castillo MF; Salgado-Canales D; Arrese M; Barrera F; Mikhailidis DP
    Curr Vasc Pharmacol; 2024; 22(3):187-202. PubMed ID: 38321893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia.
    Mehta A; Lee TB; Alebna P; Grandhi GR; Dixon DL; Salloum FN; Sanyal AJ; Siddiqui MS
    J Clin Lipidol; 2023; 17(6):828-833. PubMed ID: 37957050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH).
    Wu J; Zhang R; Shen F; Yang R; Zhou D; Cao H; Chen G; Pan Q; Fan J
    Med Sci Monit; 2018 Oct; 24():6946-6967. PubMed ID: 30270343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
    Fernández Rodríguez CM; Aller R; Gutiérrez García ML; Ampuero J; Gómez-Camarero J; Martín-Mateos RMª; Burgos-Santamaría D; Rosales JM; Aspichueta P; Buque X; Latorre M; Andrade RJ; Hernández-Guerra M; Romero-Gómez M
    Rev Esp Enferm Dig; 2019 Apr; 111(4):264-269. PubMed ID: 30810330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.
    Houttu V; Bouts J; Vali Y; Daams J; Grefhorst A; Nieuwdorp M; Holleboom AG
    Front Endocrinol (Lausanne); 2022; 13():1032164. PubMed ID: 36407307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
    Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
    World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Polyzos SA; Aronis KN; Kountouras J; Raptis DD; Vasiloglou MF; Mantzoros CS
    Diabetologia; 2016 Jan; 59(1):30-43. PubMed ID: 26407715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Lin Y; Wang W; Feng S; Zhong B
    Clin Transl Gastroenterol; 2022 Jul; 13(7):e00504. PubMed ID: 35608296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.
    Gudan A; Jamioł-Milc D; Hawryłkowicz V; Skonieczna-Żydecka K; Stachowska E
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease.
    Liu Y; Chen H; Wang J; Zhou W; Sun R; Xia M
    Am J Clin Nutr; 2015 Jul; 102(1):130-7. PubMed ID: 25948673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.